Objectives: We sought to assess the feasibility and reproducibility of 3-dimensional ultrasound molecular imaging (USMI) of vascular endothelial growth factor receptor 2 (VEGFR2) expression in tumor angiogenesis using a clinical matrix array transducer and a clinical grade VEGFR2-targeted contrast agent in a murine model of human colon cancer. Materials and Methods: Animal studies were approved by the Institutional Administrative Panel on Laboratory Animal Care. Mice with human colon cancer xenografts (n = 33) were imaged with a clinical ultrasound system and transducer (Philips iU22; X6-1) after intravenous injection of either clinical grade VEGFR2-targeted microbubbles or nontargeted control microbubbles. Nineteen mice were scanned twice to assess imaging reproducibility. Fourteen mice were scanned both before and 24 hours after treatment with either bevacizumab (n = 7) or saline only (n = 7). Three-dimensional USMI data sets were retrospectively reconstructed into multiple consecutive 1-mm-thick USMI data sets to simulate 2-dimensional imaging. Vascular VEGFR2 expression was assessed ex vivo using immunofluorescence. Results: Three-dimensional USMI was highly reproducible using both VEGFR2-targeted microbubbles and nontargeted control microbubbles (intraclass correlation coefficient, 0.83). The VEGFR2-targeted USMI signal significantly (P = 0.02) decreased by 57% after antiangiogenic treatment compared with the control group, which correlated well with ex vivo VEGFR2 expression on immunofluorescence (ρ = 0.93, P = 0.003). If only central 1-mm tumor planes were analyzed to assess antiangiogenic treatment response, the USMI signal change was significantly (P = 0.006) overestimated by an average of 27% (range, 2%-73%) compared with 3-dimensional USMI. Conclusions: Three-dimensional USMI is feasible and highly reproducible and allows accurate assessment and monitoring of VEGFR2 expression in tumor angiogenesis in a murine model of human colon cancer.
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1,2 Numerous malignancies, including colorectal cancer, secrete angiogenic growth factors that aid in the local growth and metastatic spread of disease. 3 Vascular endothelial growth factors (VEGFs) are among the beststudied factors that promote angiogenesis in tumors via binding to various receptors. The interaction with the VEGF receptor 2 (VEGFR2) specifically is key in the signaling cascade that is responsible for endothelial cell proliferation and migration; this ultimately contributes to neovascularization and tumor growth. 4, 5 Several therapies targeted at VEGF, VEGFR, or downstream signaling pathways are being evaluated in multiple clinical trials including in patients with metastatic colorectal cancer. 6 Medical imaging plays an important role in evaluating the response of patients undergoing these targeted therapies. Currently, Response Evaluation Criteria in Solid Tumors reporting is used to standardize tumor measurements and determine the responses to therapies in clinical trials. However, many targeted therapies exert cytostatic rather than cytotoxic effects and lead to little change in tumor size despite there being substantial clinical benefit for the patient. 7 Therefore, several alternative noninvasive quantitative imaging methods for evaluating treatment response at the molecular level are currently being explored. [8] [9] [10] Ultrasound molecular imaging (USMI) using molecularly targeted contrast microbubbles is one of the emerging imaging modalities for evaluating treatment response to targeted therapies at the molecular level. Some of the inherent advantages of ultrasound include its excellent spatial and temporal resolution, low cost, and wide availability. Moreover, ultrasound can be performed at the bedside in patients with significant comorbidities, and the use of microbubbles as contrast agents is safe in patients with renal insufficiency, because there are no known nephrotoxic effects. [11] [12] [13] [14] Microbubbles that target angiogenesis markers such as VEGFR2 allow for the quantification of tumor angiogenesis at the molecular level. Two-dimensional (2D) USMI using microbubbles targeted at VEGFR2 has been introduced to assess antiangiogenic therapeutic response with high accuracy using immunofluorescence as the reference standard. [15] [16] [17] However, heterogeneity in tumor tissue secondary to focal areas of necrosis, hemorrhage, or hypoxia can lead to sampling errors with 2D imaging approaches. This becomes particularly problematic when repetitive imaging is required and the transducer must be placed at the exact same position for 2D imaging to allow longitudinal assessment of treatment changes. [18] [19] [20] Three-dimensional (3D) USMI would have the advantage of measuring expression levels of molecular markers in a more accurate way by including the entire target lesion within the field of view. A recent study using a mechanically stepped transducer has shown that 3D USMI allows more robust molecular marker assessment compared with single plane 2D imaging in a rat fibrosarcoma model. 21 However, this approach used a linear motion stage to mechanically move the transducer over the target region, making it difficult to translate into the clinic. 22 The recent introduction of next-generation clinical matrix array transducers with microbeam formers has made 3D USMI of tumor angiogenesis possible without having to mechanically move the transducer, but rather allowing it to be held in a stable position similar to routine ultrasound imaging in the clinic. 23 The purpose of our study was to assess the feasibility and reproducibility of 3D USMI of VEGFR2 expression in tumor angiogenesis using a clinical matrix array transducer and a clinical grade VEGFR2-targeted contrast agent in a murine model of human colon cancer.
MATERIALS AND METHODS

Human Colon Cancer Xenografts in Mice
This study was approved by the Institutional Administrative Panel on Laboratory Animal Care. Female nude mice (Charles River; 6-8 weeks old, weighing 20-25 g) were used for the human colon cancer xenograft model. Human LS174T colon adenocarcinoma cells (ATCC, Manassas, VA) were cultured in Minimum Essential Medium supplemented with 10% fetal bovine serum and grown to 70% to 80% confluency before trypsinization and preparation for injection. 3 Â 10 6 cells were suspended in 50 μL of Matrigel (BD Biosciences, San Jose, CA) and then injected subcutaneously on the lower hind limb. Tumors were scanned at 7 to 14 days after tumor cell injection when the tumors had reached 1 to 2 cm in maximum diameter (mean size, 1.6 cm) by using an electronic caliper available on the ultrasound system.
Clinical Grade VEGFR2-Targeted Contrast Microbubbles and Control Microbubbles
Clinical grade VEGFR2-targeted contrast microbubbles (MB VEGFR2 ; BR55; Bracco Suisse SA, Geneva, Switzerland) were used in this study. These microbubbles contain a mixture of perfluorobutane and nitrogen and are functionalized with lipopeptides consisting of a VEGFR2-binding heterodimeric peptide (5.5 kDa; dissociation constant, KD = 0.5 nmol/L) and the phospholipid 1,2-distearoylsn-glycerol-3-phosphoethanolamine-N-[amino (polyethylene glycol)-2000]. [24] [25] [26] The mean number of heterodimeric peptides per square millimeter of the microbubble shell was 34,200 ± 1300 (range, 31,800-36,600). The mean diameter of MB VEGFR2 as assessed by using a cell counter and sizer (Multisizer III Coulter Counter; Beckman Coulter, Fullerton, CA) was 1.5 ± 0.1 μm (range, 1-3 μm). Nontargeted microbubbles that lack the VEGFR2-specific lipopeptide were used as control microbubbles (MB Control ; Bracco). The binding specificity of MB VEGFR2 to murine VEGFR2 was confirmed previously. 15 In Vivo 3D USMI
Imaging Protocol
All mice were kept anesthetized with 2% isoflurane in room air (administered at 2 L/min) and placed on a heated stage in prone position. Three-dimensional USMI of the tumors was performed using a clinical iU22 ultrasound machine and a clinical xMatrix transducer (x6-1, center frequency, 3.2 MHz, 9212 elements, Philips Medical Systems, Bothel, WA). The imaging data was acquired with electronic interrogation of a region of interest (ROI) without moving the transducer. The imaging parameters were as follows: voxel dimension, 320 Â 110 Â 210 μm 3 ; focal length, 40 mm; mechanical index, 0.05; dynamic range, 40 dB; volume rate, 1 vol/s. All imaging parameters were kept constant for each animal. The transducer was placed in a fixed position using a clamp and coupled to the tumor of the animals using prewarmed ultrasound gel. To bring the depth of the tumor beyond the near-field zone of the clinical transducer, an acoustic standoff of 4 cm was created with ultrasound gel (Fig. 1) . In all mice, both MB VEGFR2 and MB Control were tested and injected in random order to minimize any bias from the injection order. Via a 27g needle (Vevo Micromarker; VisualSonics, Toronto, Canada) placed in a tail vein, either 5 Â 10 7 MB VEGFR2 (100 μL) or MB Control (100 μL) were injected within a 5-second bolus at a constant injection rate by using an infusion pump (Kent Scientific, Torrington, CT). A minimum of 30 minutes of waiting time between microbubble injections was observed to allow clearance of microbubbles from previous injections. [27] [28] [29] First, B-mode images were acquired to define the anatomy and to delineate the tumor volume. Then, image acquisition was switched to Power Modulation Contrast mode, and MB VEGFR2 or MB Control were injected. After 4 minutes, which allowed the microbubbles to circulate through the tumor volume, imaging was performed for 15 seconds to obtain predestruction ultrasound imaging signal, corresponding to the signal from molecularly attached and freely circulating microbubbles. 15, 28, 30 Then, a sequence of 5 volumes with high-power destructive pulses (mechanical index, 0.77) during a 5-second period was applied to destroy all microbubbles in the field of view. After the microbubble destruction, 60 seconds were given to allow microbubbles to recirculate into the tumor volume and imaging data sets after the destruction were obtained for 15 seconds corresponding to imaging signal from freely circulating microbbubles. Ultrasound imaging volumes were streamed in real time using the built-in Digital Navigation Link of the ultrasound machine with custom in-house MevisLab modules written in C++. 31 
Assessment of Reproducibility of 3D USMI
To test the reproducibility of 3D USMI, in 19 tumor-bearing mice, the previously mentioned imaging protocol was repeated twice both after MB VEGFR2 and MB Control injections, respectively (Fig. 2) . The different contrast agent injections were separated by at least a 30-minute waiting time to allow clearance of microbubbles from previous injections. [27] [28] [29] All mice tolerated the 4 repetitive injections of contrast agents well.
Monitoring Antiangiogenic Treatment Response With 3D USMI
In an additional group of 14 tumor-bearing mice, the effects of a single dose of antiangiogenic treatment (n = 7) with bevacizumab (Avastin, 10 mg/kg intravenous; Genentech, South San Francisco, CA) versus control treatment with intravenous saline only (n = 7) on the 3D USMI signal were tested (Fig. 2) . First, the mice underwent baseline VEGFR2-targeted scanning at day 0 using the protocol described previously. After treatment with either antiangiogenic therapy or saline only, 3D USMI was repeated 24 hours later using the same imaging protocol. After scanning at 24 hours, all animals were killed and tumor tissues were harvested for ex vivo analysis. FIGURE 1. Photograph of the imaging setting for 3D USMI using a clinical matrix array transducer in mice. To bring the subcutaneous human colon cancer xenograft implanted on the hind limb beyond the near field zone of the transducer, the transducer was embedded in a custom standoff, which was composed of a column of prewarmed ultrasound gel contained within a plastic cylindrical chamber. All mice were kept under inhalation anesthesia during scanning, and body temperature was kept constant by placing them on a gel pad on a heated scanning station. Note that a needle was placed in 1 of the 2 tail veins to allow intravenous administration of contrast microbubbles. Figure 1 can be viewed online in color at www.investigativeradiology.com.
Analysis of 3D USMI Data Sets
All imaging data sets were analyzed in random order by 1 reader blinded to the microbubble types (MB VEGFR2 versus MB Control ) and to the treatments (antiangiogenic versus saline treatment). Data processing was performed with an in-house custom software developed from MeVisLab. 32 In brief, using B-mode imaging data collected before contrast agent administration, a volume of interest was manually contoured on the 3D B-mode images visualized on axial, sagittal, and coronal planes for each series, covering the entire tumor volume. The software automatically calculated all tumor volumes; the average tumor volume was 2145 mm 3 (range, 524-4189 mm 3 ). The imaging signal of attached microbubbles to VEGFR2 was calculated as the difference of imaging signal intensity (in arbitrary units; a.u.) between predestructive and postdestructive linearized imaging signals. 15, 33, 34 To evaluate discrepancies in quantifying treatment effects on the basis of 3D imaging versus imaging in 2D, the acquisition of multiple quasi-2D imaging data sets was simulated by retrospectively segmenting the 3D USMI data sets into multiple consecutive 1-mmthick slices. The ROIs were manually drawn over all consecutive 1-mm slices, and imaging signal intensity changes before and after the antiangiogenic treatment were measured for each 1-mm slice. To assess the degree to which a single 1-mm slice could misrepresent antiangiogenic treatment response of tumors compared with 3D imaging of the entire tumor volume, ratios of imaging signals after and before the antiangiogenic treatment obtained from each 1-mm slice were compared with the ratios of imaging signals after and before treatment obtained from 3D imaging, and the percentage differences between those ratios were calculated.
Ex Vivo Analysis of Tumors
Before extraction, all tumors were marked on the cranial and caudal edges (elevational direction from head to feet in ultrasound imaging) as well as at the dorsal and left tumor surfaces using dyes with 4 different colors (Davidson Marking System; Bradley Products, Bloomington, MN). This allowed preservation of the spatial orientation of tumor tissues during tissue fixation and sectioning.
Tumor tissues were fixed in 4% paraformaldehyde overnight at 4°C and then cryopreserved in a 30% sucrose solution. Samples were placed in optimal cutting temperature media (OCT; Tissue-Tek, Sukura Finetek, Torrance, CA), frozen, and then sectioned into multiple 1-mm blocks by using a cryomicrotome to allow approximate alignment with the 1-mm slices reconstructed from the 3D data sets. Out of each 1-mm tissue block, a representative 10-μm section from the center of the block was selected for quantification of VEGFR2 expression and percentage area of blood vessels (see subsequent paragraphs).
Expression of VEGFR2 was visualized using standard immunofluorescence procedures. In brief, sections were incubated in phosphate buffered saline for 10 minutes to remove remaining OCT and permeabilized for 10 minutes in 0.5% Triton-X 100 in phosphate buffered saline. The sections were blocked in a solution containing 3% bovine serum albumin (Sigma, St Louis, MO), 3% goat serum (Sigma), and 3% donkey serum (Sigma) for 30 minutes at room temperature before incubation with primary antibodies overnight [1:100 rabbit-antimouse VEGFR2 (Cell Signaling, Danvers, MA), and 1:250 rat antimouse CD31 (eBioscience, San Jose, CA)]. Primary antibodies were visualized with 1:250 AlexaFluor 546 goat antirabbit immunoglobulin G (IgG) (Invitrogen, Grand Island, NY) and with 1:250 AlexaFluor488 FIGURE 2. Overview of the experimental design. In 33 nude mice, subcutaneous human colon cancer xenografts were randomized into 3 groups. In group 1 (n = 19), 2 consecutive 3D USMI examinations using MB VEGFR2 and MB Control each in random order in the same imaging session were performed to assess reproducibility of the imaging technique (total of 4 injections). The mice in group 2 (n = 7) were scanned before and 24 hours after a single dose of bevacizumab; the mice in group 3 (n = 7) served as the control group without antiangiogenic treatment. After the scanning, tumor tissues were harvested for ex vivo analysis. Figure 2 can be viewed online in color at www.investigativeradiology.com. donkey antirat IgG (Invitrogen). Samples were mounted in aqueous mounting media (BiogeneX, San Ramon, CA), and fluorescent images were acquired using Metamorph software (Universal Imaging Corp, West Chester, PA) and a LSM510 metaconfocal microscope (Zeiss, Maple Grove, MN) attached to a digital camera (AxioCam MRc, Bernried, Germany). Multiple single confocal slices (10 μm) were collected and displayed using a 20Â objective. By using ImageJ software (National Institutes of Health, Bethesda, MD), both VEGFR2 expression and the percentage area of blood vessels per field of view were quantified as the average value from at least 5 randomly selected fields of view (single field of view area, 0.19 mm 2 ) in the different tumor slices. In each field, CD31 was used to identify blood vessels, and the mean fluorescent intensity of VEGFR2 within the ROI and percentage area of blood vessels (guided by CD31 staining) were measured in treated and control tumors. Both the overall mean expression of VEGFR2 and the mean percentage area of blood vessels per whole tumor volume were calculated by averaging the respective values obtained from all consecutive slices per tumor.
Statistical Analysis
All continuous measurements were expressed as means ± standard deviation. To measure the reproducibility of 3D USMI using both MB VEGFR2 and MB Control , intraclass correlation coefficients (ICCs), along with 95% confidence intervals (CIs), were calculated. 35 Signal intensities obtained in the same mice using both MB VEGFR2 and MB Control were compared with the paired t test. Changes in imaging signal using MB VEGFR2 at 24 hours after either antiangiogenic or saline-only treatment were compared using a 2-sample Wilcoxon rank test. To show slice-to-slice variability in simulated 2D imaging, the coefficient of variation was calculated as the ratio between the standard deviation and the meanvalue of imaging signals from all the 1-mm slices for the same tumor. The Spearman correlation coefficient (ρ) between invivo 3D USMI signals and ex vivo VEGFR2 expression levels from the same mice was calculated. All statistical analyses were performed with commercially available software (IBM SPSS statistics software, version 20; IBM Corp, Chicago, IL). The significance level was set at 0.05.
RESULTS
Reproducibility of 3D USMI
In the tumor-bearing animals undergoing 2 consecutive injections of both MB VEGFR2 and MB Control , respectively, the overall reproducibility of 3D USMI was excellent for both microbubble types (Fig. 3) .
Using MB VEGFR2 , the average imaging signal in human colon cancer xenografts was 1.11Â10 6 ± 5.70Â10 5 a.u. after the first contrast agent injection. This was not significantly different (P = 0.07) compared FIGURE 3. Representative subcutaneous human colon cancer xenograft imaged twice with both MB VEGFR2 and MB Control . Transverse, sagittal, and coronal views through the center of the tumor (arrows) are shown. Note that there are similar signal distribution on repeated scans using both contrast agent types and substantially higher imaging signal using MB VEGFR2 compared with MB Control in the same tumor. Scale bar is 10 mm. Figure 3 ) in the saline-only control group versus 1760 ± 525 mm 3 in the antiangiogenic treatment group. At 24 hours after the treatment, the tumor volume increased by 16% ± 18% (P = 0.52) in the control group compared with baseline and by 8% ± 11% (P = 0.57) in the treatment group; the tumor volumes in the 2 animal groups remained not significantly different between both treatment groups (P = 0.14). In contrast, after a single dose of bevacizumab, 3D USMI signal in human colon cancer xenografts significantly decreased by an average of 57% (P = 0.02; Fig. 4 ). Three-dimensional USMI signal increased by an average of 26% within 1 day in the control animals treated with saline only (P = 0.41).
Comparison of USMI Signal Intensities on 3D Versus Quasi-2D Data Sets
Overall, VEGFR2-targeted USMI signal intensities obtained from multiple 1-mm planes reconstructed at 1-mm increments showed substantial spatial heterogeneity within the tumors before treatment (coefficient of variation, 0.43; 95% CI, 0.35-0.51). This spatial heterogeneity further increased significantly (P = 0.006) after the antiangiogenic treatment (coefficient of variation, 1.1; 95% CI, 0.45-1.77; Fig. 5) .
To assess the degree to which a single 1-mm plane could misrepresent antiangiogenic treatment response of tumors compared with 3D imaging of the entire tumor volume, ratios of imaging signals after and before the antiangiogenic treatment obtained from the 1-mm slices were compared with the ratios of imaging signals after and before treatment obtained from 3D imaging, and percentage differences between each 2D slice and 3D are plotted in Figure 6 . To further evaluate how quantitative assessment of treatment response would change if only the central tumor plane was analyzed, the percentage differences in signal intensity changes before and after the antiangiogenic treatment were calculated for each animal for both the 3D and the central 1-mm images. In all tumors, treatment response was significantly overestimated (P = 0.006) by an average of 27% (range, 2%-73%) on central planes versus 3D imaging.
Ex Vivo Analysis of Tumors
After the antiangiogenic treatment, VEGFR2 expression levels on immunofluorescence in human colon cancer xenografts was significantly (P = 0.03) smaller (9.9 ± 2.3 a.u.) compared with saline-treated tumors (16.8 ± 4.3 a.u.), which correlated well with in vivo 3D USMI imaging signal (ρ = 0.93, P = 0.003; Fig. 4) . Similarly, the percentage FIGURE 4. A, The effect of antiangiogenic treatment on VEGFR2-targeted 3D USMI signal in representative subcutaneous human colon cancer xenograft. Three-dimensional USMI signal, as visualized on transverse, sagittal, and coronal views, substantially decreased 24 hours after administration of bevacizumab (lower row) compared with baseline imaging (upper row); scale bar is10 mm. B, Photomicrographs of merged (yellow), VEGFR2 (red), and CD31 (green) stained tissue slices obtained from the tumor center in the same mouse confirmed treatment effect with both decreased VEGFR2 expression levels and percentage area of blood vessels in bevacizumab-treated versus saline-treated tumor; scale bar is 100 μm. Figure 4 can be viewed online in color at www.investigativeradiology.com.
area of blood vessels was significantly (P = 0.03) decreased in bevacizumab-treated (1.7% ± 0.9%) compared with saline-treated tumors (5.9% ± 3.7%). Furthermore, quantitative immunofluorescence analysis of multiple consecutive 1-mm tissue blocks showed substantial variance of both VEGFR2 expression (coefficient of variation, 0.51; 95% CI, 0.32-0.71) and percentage area of blood vessels (coefficient of variation, 1.00; 95% CI, 0.1-2.06) across the tumors.
DISCUSSION
Our results suggest that 3D USMI using a clinical ultrasound system and a clinical grade VEGFR2-targeted contrast agent is both feasible and highly reproducible and allows for the assessment of antiangiogenic treatment response in a human colon cancer xenograft model. In addition, our results show spatial heterogeneity of VEGFR2 expression in tumors, suggesting that 3D USMI may be more robust for assessing tumor angiogenesis than the traditional 2D USMI.
Human solid tumors are biologically heterogeneous on both genetic and histopathological levels, which is reflected by the spatial variations in cellular density, angiogenesis, and microenvironmental components. 36, 37 Regarding angiogenesis, it has been shown that VEGF expression is heterogeneously distributed within solid tumors and undergoes dynamic change during tumor growth. 38 Being able to account for this heterogeneity is critical in characterizing malignancies, predicting the clinical outcomes of antiangiogenic therapies, and assessing therapeutic responses. 39, 40 Various imaging modalities are being explored to noninvasively assess angiogenesis, including magnetic resonance imaging, 39, 40 computed tomography, [41] [42] [43] positron emission tomography, 44 and ultrasound. 21 Ultrasound is advantageous owing to its relatively low cost, wide availability, and the lack of radiation exposure, which allows multiple repetitive examinations that may be helpful in the future design of more individualized treatment regimens. Although 2D USMI has been shown to be an effective tool for imaging and monitoring angiogenesis, [15] [16] [17] a potential drawback is the difficulty of assessing the spatial and temporal intratumoral angiogenesis heterogeneity due to the limitation of imaging only 1 arbitrary plane. This problem is compounded when longitudinally assessing changes in tumor neovascularity. Therefore, the assessment of tumor angiogenesis along the entire 3D volume in cancer is critically important for USMI if it is to be further developed for monitoring treatment response in patients.
Recently, the feasibility of 3D USMI has been explored in 8 subcutaneous rat fibrosarcoma tumors imaged with an α v β 3 integrintargeted contrast agent. 21 In that study, a linear array 15L8 transducer was mechanically stepped elevationally in 800-μm increments over the tumor volume and multiple 2D data were merged into a single 3D USMI data set. In our study, we explored whether 3D USMI can be further refined to reproducibly assess tumor angiogenesis by using a clinical matrix array transducer. This transducer allows quantification of molecular marker expression levels over an entire tumor volume at a fixed position without the need for mechanically moving the transducer over the tumor. Nineteen tumors were imaged twice both with molecularly targeted and nontargeted contrast agents. Our results showed that 3D USMI was highly reproducible for both contrast agent types with an ICC value of 0.83 each. Also, 3D USMI signal intensities using VEGFR2-targeted microbubbles were substantially higher compared with nontargeted microbubbles, confirming target specificity of the clinical grade VEGFR2-targeted contrast agent used in our study, as shown previously by 2D USMI in various animal models. 15, 26, [45] [46] [47] [48] We then tested 3D USMI for in vivo monitoring of tumor angiogenesis during the antiangiogenic treatment with bevacizumab in a clinically relevant human colon cancer xenograft model. Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that comprise the human framework regions (approximately 93% human and 7% murine protein sequence), 49 which has been shown to be effective in human cancer xenograft models in mice 50 and which is currently used in patients with colorectal cancer and various other cancer types. [51] [52] [53] [54] In vivo 3D USMI signal substantially decreased as early as 24 hours after a single dose of bevacizimab. In contrast, 3D USMI remained substantially higher in the control mice receiving saline only. Notably, tumor sizes were not significantly different in treated versus nontreated mice within 24 hours, suggesting that 3D USMI allows early antiangiogenic treatment effect assessment before overt morphologic-anatomic changes of the tumor become visible. This was further corroborated by quantitative immunofluorescence used as reference standard confirming decreased VEGFR2 expression levels along with decreased percentage area of blood vessels in treated tumors.
We further assessed the effects of 3D USMI compared with simulated 2D USMI in terms of assessing quantitative changes in USMI signal intensities after antiangiogenic therapy. For this purpose, the 3D USMI data sets of each tumor were retrospectively reconstructed into multiple 1-mm slices in 1-mm increments. Our data showed substantial slice-to-slice variability of USMI signals, at both baseline and even more pronounced after the antiangiogenic treatment. More importantly, treatment effects were substantially overestimated or underestimated when single 2D slices were analyzed compared with 3D USMI. Variability between 2D and 3D USMI in terms of assessment of treatment effects was smaller for the central 2D planes representing the largest tumor diameter, which is usually chosen for 2D ultrasound imaging to represent the entire tumor volume. 34, 45 However, treatment response was still overestimated by, on average, 27% on the central plane compared with 3D USMI, which would make assessment of subtle differences in treatment response in patients difficult. Because histopathologic proof of treatment response as the ultimate reference standard is invasive, expensive, practically challenging, and often not representative for the entire tumor because only a small portion of the tumor is being biopsied, 55 3D USMI may become a promising new surrogate end point for assessing treatment response in patients with cancer. Spatial heterogeneity of tumor angiogenesis demonstrated for all 7 subcutaneous human colon cancer xenografts imaged with VEGFR2-targeted USMI before (black box plots) and 24 hours after (red box plots) antiangiogenic therapy with bevacizumab. Three-dimensional data sets were retrospectively segmented into different numbers (depending on tumor size) of consecutive 1-mm data sets, and logarithmically transformed imaging signals were then plotted for each animal separately. Each box in the plot represents the 25th and 75th quartiles, the line inside each box identifies the median, and the whiskers indicate the fifth and 95th percentile of measurements excluding the outliers. Asterisks represent outliers. Note the substantial ranges of USMI signal intensities among consecutive 1-mm planes both before and after antiangiogenic therapy. Figure 5 can be viewed online in color at www.investigativeradiology.com.
We acknowledge several limitations of our study. First, in this proof-of-principle study, only early effects of the antiangiogenic treatment on 3D USMI were assessed at 24 hours. Future studies are warranted to assess its value for monitoring treatment response in cancer for a longer period of time and to evaluate the prognostic value of early molecular imaging changes in terms of survival outcomes. Second, we did not obtain 3D ultrasound perfusion data in the same animals along with 3D USMI data sets to assess how molecular imaging compares with functional imaging as a quantitative surrogate marker for antiangiogenic treatment response assessment in cancer. Future studies are warranted, comparing both functional and molecular imaging in the same tumors in intra-animal comparison experiments.
In conclusion, our results suggest that 3D USMI using a clinical ultrasound system and matrix array transducer is technically feasible and highly reproducible for assessing tumor angiogenesis in a human colon cancer xenograft model in mice. In addition, 3D USMI using a clinical grade VEGFR2-targeted contrast agent, which has entered clinical trials most recently, 56 allows noninvasive quantification of antiangiogenic therapeutic effects and may better account for heterogeneity of tumor angiogenesis compared with the traditional 2D USMI. The introduction of 3D imaging capabilities on clinical ultrasound systems may further stimulate the future use of USMI in the clinic for objective and reliable monitoring of molecularly targeted treatment effects.
